MedTrace Logo

Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face

NCT04892407 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2022-06-27

No results posted yet for this study

Summary

A prospective, randomized, controlled study of Algeness® DF 3.5% Deep Volumizing Filler comparing to Juvéderm Voluma to correct midface volume loss.

Conditions

  • Age-Related Volume Deficit in the Mid-Face

Interventions

DEVICE

Algeness® DF 3.5%

dermal filler CE Mark approved for treatment of cheek and midface volume loss

DEVICE

Juvéderm Voluma

dermal filler CE Mark approved for treatment of cheek and midface volume loss

Sponsors & Collaborators

  • Advanced Aesthetic Technologies, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2022-12-31
Completion
2024-08-31

Countries

  • Belgium
  • France
  • Germany
  • Israel
  • Malaysia
  • Spain
  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892407 on ClinicalTrials.gov